GlaxoSmithKline, Merck to Trial New Cancer Treatment
November 03 2015 - 7:00AM
Dow Jones News
LONDON-- GlaxoSmithKline PLC (GSK.LN) said Tuesday that it and
Merck & Co. Inc. (MRK) will trial a combination of two separate
drugs as a potential cancer treatment.
The companies will commence human trails to evaluate Glaxo's
investigational immunotherapy GSK3174998 as monotherapy in
combination with Merck's anti-PD-1 therapy Keytruda in patients
with tumors that have progressed after standard treatment.
Shares of Glaxo at 1227 GMT trading 0.04% lower at 1,397
pence.
Write to Tapan Panchal at tapan.panchal@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 03, 2015 07:45 ET (12:45 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024